Stability of gabexate mesilate products

Influence of the addition of mannitol

Miyuki Sakurai, Hiroyuki Abe, Noboru Okamura, Yohei Inoue, Takeshi Akiyoshi, Kenji Matsuyama, Takahiro Uchida, Makoto Otsuka

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Gabexate mesilate is a non-peptide protease inhibitor, developed in Japan, which is used in the treatment of acute pancreatitis and disseminated intravascular coagulation. This compound is readily hydrolyzed as it has ester bonds in its structure. It is now out of patent in Japan and there are many generic versions on the market. The crystal structure and the hydrolysate content of the branded product and nine generic versions were evaluated by X-ray diffractometry, thermal analysis and HPLC. The results showed that generic products containing mannitol as an additive had a higher content of hydrolysate as an impurity than the branded product or generic products formulated without mannitol, suggesting that the crystal structure might be altered and stability impaired in mannitol-containing drug products.

Original languageEnglish
Pages (from-to)13-20
Number of pages8
JournalBio-Medical Materials and Engineering
Volume20
Issue number1
DOIs
Publication statusPublished - 2010

Fingerprint

Gabexate
Mannitol
Crystal structure
Coagulation
Drug products
X ray diffraction analysis
Thermoanalysis
Esters
Impurities
Protease Inhibitors

Keywords

  • Gabexate mesilate
  • Generic products
  • Mannitol

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biomaterials

Cite this

Stability of gabexate mesilate products : Influence of the addition of mannitol. / Sakurai, Miyuki; Abe, Hiroyuki; Okamura, Noboru; Inoue, Yohei; Akiyoshi, Takeshi; Matsuyama, Kenji; Uchida, Takahiro; Otsuka, Makoto.

In: Bio-Medical Materials and Engineering, Vol. 20, No. 1, 2010, p. 13-20.

Research output: Contribution to journalArticle

Sakurai, M, Abe, H, Okamura, N, Inoue, Y, Akiyoshi, T, Matsuyama, K, Uchida, T & Otsuka, M 2010, 'Stability of gabexate mesilate products: Influence of the addition of mannitol', Bio-Medical Materials and Engineering, vol. 20, no. 1, pp. 13-20. https://doi.org/10.3233/BME-2010-0611
Sakurai, Miyuki ; Abe, Hiroyuki ; Okamura, Noboru ; Inoue, Yohei ; Akiyoshi, Takeshi ; Matsuyama, Kenji ; Uchida, Takahiro ; Otsuka, Makoto. / Stability of gabexate mesilate products : Influence of the addition of mannitol. In: Bio-Medical Materials and Engineering. 2010 ; Vol. 20, No. 1. pp. 13-20.
@article{fb86c4bd7fd443dfb5c48dfed58e68bf,
title = "Stability of gabexate mesilate products: Influence of the addition of mannitol",
abstract = "Gabexate mesilate is a non-peptide protease inhibitor, developed in Japan, which is used in the treatment of acute pancreatitis and disseminated intravascular coagulation. This compound is readily hydrolyzed as it has ester bonds in its structure. It is now out of patent in Japan and there are many generic versions on the market. The crystal structure and the hydrolysate content of the branded product and nine generic versions were evaluated by X-ray diffractometry, thermal analysis and HPLC. The results showed that generic products containing mannitol as an additive had a higher content of hydrolysate as an impurity than the branded product or generic products formulated without mannitol, suggesting that the crystal structure might be altered and stability impaired in mannitol-containing drug products.",
keywords = "Gabexate mesilate, Generic products, Mannitol",
author = "Miyuki Sakurai and Hiroyuki Abe and Noboru Okamura and Yohei Inoue and Takeshi Akiyoshi and Kenji Matsuyama and Takahiro Uchida and Makoto Otsuka",
year = "2010",
doi = "10.3233/BME-2010-0611",
language = "English",
volume = "20",
pages = "13--20",
journal = "Bio-Medical Materials and Engineering",
issn = "0959-2989",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - Stability of gabexate mesilate products

T2 - Influence of the addition of mannitol

AU - Sakurai, Miyuki

AU - Abe, Hiroyuki

AU - Okamura, Noboru

AU - Inoue, Yohei

AU - Akiyoshi, Takeshi

AU - Matsuyama, Kenji

AU - Uchida, Takahiro

AU - Otsuka, Makoto

PY - 2010

Y1 - 2010

N2 - Gabexate mesilate is a non-peptide protease inhibitor, developed in Japan, which is used in the treatment of acute pancreatitis and disseminated intravascular coagulation. This compound is readily hydrolyzed as it has ester bonds in its structure. It is now out of patent in Japan and there are many generic versions on the market. The crystal structure and the hydrolysate content of the branded product and nine generic versions were evaluated by X-ray diffractometry, thermal analysis and HPLC. The results showed that generic products containing mannitol as an additive had a higher content of hydrolysate as an impurity than the branded product or generic products formulated without mannitol, suggesting that the crystal structure might be altered and stability impaired in mannitol-containing drug products.

AB - Gabexate mesilate is a non-peptide protease inhibitor, developed in Japan, which is used in the treatment of acute pancreatitis and disseminated intravascular coagulation. This compound is readily hydrolyzed as it has ester bonds in its structure. It is now out of patent in Japan and there are many generic versions on the market. The crystal structure and the hydrolysate content of the branded product and nine generic versions were evaluated by X-ray diffractometry, thermal analysis and HPLC. The results showed that generic products containing mannitol as an additive had a higher content of hydrolysate as an impurity than the branded product or generic products formulated without mannitol, suggesting that the crystal structure might be altered and stability impaired in mannitol-containing drug products.

KW - Gabexate mesilate

KW - Generic products

KW - Mannitol

UR - http://www.scopus.com/inward/record.url?scp=77952072079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952072079&partnerID=8YFLogxK

U2 - 10.3233/BME-2010-0611

DO - 10.3233/BME-2010-0611

M3 - Article

VL - 20

SP - 13

EP - 20

JO - Bio-Medical Materials and Engineering

JF - Bio-Medical Materials and Engineering

SN - 0959-2989

IS - 1

ER -